Circulating exosomal gastric cancer-associated long noncoding RNA1 as a noninvasive biomarker for predicting chemotherapy response and prognosis of advanced gastric cancer: A multi-cohort, multi-phase study.
Circulating exosomal gastric cancer-associated long noncoding RNA1 as a noninvasive biomarker for predicting chemotherapy response and prognosis of advanced gastric cancer: A multi-cohort, multi-phase study.
复制标题
循环外泌体胃癌相关长非编码RNA1作为预测晚期胃癌化疗反应和预后的非侵入性生物标志物：一项多队列、多阶段研究
DOI：
10.1016/j.ebiom.2022.103971
复制
发表时间：
2022-04
期刊：
影响因子：
11.1
通讯作者：
Guo X
中科院分区：
文献类型：
--
作者：
Song Q;Lv X;Ru Y;Dong J;Chang R;Wu D;Chen L;Wang X;Guo X
先前验证的研究已经确定了循环外泌体lncRNA-GC 1用于检测和监测胃癌的诊断价值。我们的目的是进一步确定循环外泌体lncRNA-GC1对预后和化疗反应的预测作用。我们回顾性地进行了一项多阶段分析，包括四个独立队列的981例患者。使用训练群组来生成预测模型。招募了一个内部队列和两个外部队列作为验证队列。使用联合队列中的II期或III期胃癌患者评估循环外泌体lncRNA-GC 1对化疗反应的预测价值。在训练队列中，循环外泌体lncRNA-GC 1被确定为无病生存期和总生存期的独立预后预测因子。基于循环外泌体lncRNA-GC1和AJCC分期的预后风险分层模型显示，与单独的传统AJCC分期系统相比，无病生存期和总生存期的预测准确性更高（C指数：DFS 0.701 vs 0.614; OS 0.720 vs 0.611，均P <0.05）。并在验证队列中得到进一步验证。在交互作用分析中，对于II和III期GC，低水平的循环外泌体lncRNA-GC 1患者从辅助化疗中获得更多的生存益处（P <0.05），而高水平的患者则没有。循环外泌体lncRNA-GC 1的测量提供了临床上重要的预后信息，并可以补充AJCC阶段，以优化决策，选择手术后可从氟尿嘧啶化疗中获益更多的患者。资助者名单见鸣谢。
A previous validated study has identified the diagnostic value of circulating exosomal lncRNA-GC1 for detecting and monitoring gastric cancer. We aimed to further determine the predictive role of circulating exosomal lncRNA-GC1 for prognosis and chemotherapy response. We retrospectively conducted a multi-phase analysis with four independent cohorts of 981 patients. A training cohort was used to generate the predictive model. One internal and two external cohorts were recruited as validation cohorts. Patients with stage II or III gastric cancer in the combined cohort were used to evaluate the predictive value of circulating exosomal lncRNA-GC1 for chemotherapy response. In the training cohort, circulating exosomal lncRNA-GC1 was identified as an independent prognostic predictor for disease-free and overall survival. A prognostic risk stratification model based on circulating exosomal lncRNA-GC1 and AJCC stage revealed better predictive accuracy for disease-free and overall survival than the traditional AJCC stage system alone (C-index: DFS 0.701 vs 0.614; OS 0.720 vs 0.611, both P<0.05). And it has been further verified in the validation cohorts. In interaction analysis, for stage II and III GC, patients with low-level of circulating exosomal lncRNA-GC1 derived more survival benefit from adjuvant chemotherapy (P < 0.05); while those with high-level did not. Measurement of circulating exosomal lncRNA-GC1 provides clinically important prognostic information and could complement the AJCC stage to optimize decision-making for selecting patients who could benefit more from fluorouracil-based chemotherapy after surgery. The funders are listed in the Acknowledgement.
登录
查看更多内容
影响因子：
--
作者：
Ding G;Zhou L;Qian Y;Fu M;Chen J;Chen J;Xiang J;Wu Z;Jiang G;Cao L
通讯作者：
Cao L
DOI：
10.1111/apm.1965.64.1.31
发表时间：
1965-01-01
期刊：
ACTA PATHOLOGICA ET MICROBIOLOGICA SCANDINAVICA
影响因子：
--
作者：
LAUREN, P
通讯作者：
LAUREN, P
影响因子：
82.9
作者：
通讯作者：
--
影响因子：
82.9
作者：
Cristescu, Razvan;Lee, Jeeyun;Aggarwal, Amit
通讯作者：
Aggarwal, Amit
影响因子：
2
作者：
Kang, Le;Chen, Weijie;Petrick, Nicholas A.;Gallas, Brandon D.
通讯作者：
Gallas, Brandon D.